Depression as a Neuroendocrine Disorder: Emerging Neuropsychopharmacological Approaches beyond Monoamines
Depression is currently recognized as a crucial problem in everyday clinical practice, in light of ever-increasing rates of prevalence, as well as disability, morbidity, and mortality related to this disorder. Currently available antidepressant drugs are notoriously problematic, with suboptimal remi...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Series: | Advances in Pharmacological Sciences |
| Online Access: | http://dx.doi.org/10.1155/2019/7943481 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832553376955498496 |
|---|---|
| author | Mervin Chávez-Castillo Victoria Núñez Manuel Nava Ángel Ortega Milagros Rojas Valmore Bermúdez Joselyn Rojas-Quintero |
| author_facet | Mervin Chávez-Castillo Victoria Núñez Manuel Nava Ángel Ortega Milagros Rojas Valmore Bermúdez Joselyn Rojas-Quintero |
| author_sort | Mervin Chávez-Castillo |
| collection | DOAJ |
| description | Depression is currently recognized as a crucial problem in everyday clinical practice, in light of ever-increasing rates of prevalence, as well as disability, morbidity, and mortality related to this disorder. Currently available antidepressant drugs are notoriously problematic, with suboptimal remission rates and troubling side-effect profiles. Their mechanisms of action focus on the monoamine hypothesis for depression, which centers on the disruption of serotonergic, noradrenergic, and dopaminergic neurotransmission in the brain. Nevertheless, views on the pathophysiology of depression have evolved notably, and the comprehension of depression as a complex neuroendocrine disorder with important systemic implications has sparked interest in a myriad of novel neuropsychopharmacological approaches. Innovative pharmacological targets beyond monoamines include glutamatergic and GABAergic neurotransmission, brain-derived neurotrophic factor, various endocrine axes, as well as several neurosteroids, neuropeptides, opioids, endocannabinoids and endovanilloids. This review summarizes current knowledge on these pharmacological targets and their potential utility in the clinical management of depression. |
| format | Article |
| id | doaj-art-04afc15b35a945a79e9e3d7d575dcd26 |
| institution | Kabale University |
| issn | 1687-6334 1687-6342 |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advances in Pharmacological Sciences |
| spelling | doaj-art-04afc15b35a945a79e9e3d7d575dcd262025-02-03T05:53:59ZengWileyAdvances in Pharmacological Sciences1687-63341687-63422019-01-01201910.1155/2019/79434817943481Depression as a Neuroendocrine Disorder: Emerging Neuropsychopharmacological Approaches beyond MonoaminesMervin Chávez-Castillo0Victoria Núñez1Manuel Nava2Ángel Ortega3Milagros Rojas4Valmore Bermúdez5Joselyn Rojas-Quintero6Endocrine and Metabolic Diseases Research Center, School of Medicine, University of Zulia, Maracaibo, VenezuelaEndocrine and Metabolic Diseases Research Center, School of Medicine, University of Zulia, Maracaibo, VenezuelaEndocrine and Metabolic Diseases Research Center, School of Medicine, University of Zulia, Maracaibo, VenezuelaEndocrine and Metabolic Diseases Research Center, School of Medicine, University of Zulia, Maracaibo, VenezuelaEndocrine and Metabolic Diseases Research Center, School of Medicine, University of Zulia, Maracaibo, VenezuelaUniversidad Simón Bolívar, Departamento de Ciencias Sociales y Humanas, Cúcuta, ColombiaDivision of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02215, USADepression is currently recognized as a crucial problem in everyday clinical practice, in light of ever-increasing rates of prevalence, as well as disability, morbidity, and mortality related to this disorder. Currently available antidepressant drugs are notoriously problematic, with suboptimal remission rates and troubling side-effect profiles. Their mechanisms of action focus on the monoamine hypothesis for depression, which centers on the disruption of serotonergic, noradrenergic, and dopaminergic neurotransmission in the brain. Nevertheless, views on the pathophysiology of depression have evolved notably, and the comprehension of depression as a complex neuroendocrine disorder with important systemic implications has sparked interest in a myriad of novel neuropsychopharmacological approaches. Innovative pharmacological targets beyond monoamines include glutamatergic and GABAergic neurotransmission, brain-derived neurotrophic factor, various endocrine axes, as well as several neurosteroids, neuropeptides, opioids, endocannabinoids and endovanilloids. This review summarizes current knowledge on these pharmacological targets and their potential utility in the clinical management of depression.http://dx.doi.org/10.1155/2019/7943481 |
| spellingShingle | Mervin Chávez-Castillo Victoria Núñez Manuel Nava Ángel Ortega Milagros Rojas Valmore Bermúdez Joselyn Rojas-Quintero Depression as a Neuroendocrine Disorder: Emerging Neuropsychopharmacological Approaches beyond Monoamines Advances in Pharmacological Sciences |
| title | Depression as a Neuroendocrine Disorder: Emerging Neuropsychopharmacological Approaches beyond Monoamines |
| title_full | Depression as a Neuroendocrine Disorder: Emerging Neuropsychopharmacological Approaches beyond Monoamines |
| title_fullStr | Depression as a Neuroendocrine Disorder: Emerging Neuropsychopharmacological Approaches beyond Monoamines |
| title_full_unstemmed | Depression as a Neuroendocrine Disorder: Emerging Neuropsychopharmacological Approaches beyond Monoamines |
| title_short | Depression as a Neuroendocrine Disorder: Emerging Neuropsychopharmacological Approaches beyond Monoamines |
| title_sort | depression as a neuroendocrine disorder emerging neuropsychopharmacological approaches beyond monoamines |
| url | http://dx.doi.org/10.1155/2019/7943481 |
| work_keys_str_mv | AT mervinchavezcastillo depressionasaneuroendocrinedisorderemergingneuropsychopharmacologicalapproachesbeyondmonoamines AT victorianunez depressionasaneuroendocrinedisorderemergingneuropsychopharmacologicalapproachesbeyondmonoamines AT manuelnava depressionasaneuroendocrinedisorderemergingneuropsychopharmacologicalapproachesbeyondmonoamines AT angelortega depressionasaneuroendocrinedisorderemergingneuropsychopharmacologicalapproachesbeyondmonoamines AT milagrosrojas depressionasaneuroendocrinedisorderemergingneuropsychopharmacologicalapproachesbeyondmonoamines AT valmorebermudez depressionasaneuroendocrinedisorderemergingneuropsychopharmacologicalapproachesbeyondmonoamines AT joselynrojasquintero depressionasaneuroendocrinedisorderemergingneuropsychopharmacologicalapproachesbeyondmonoamines |